載入中
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
前收盤價
US$8.93
+US$0.01 · +0.11%
盤中時間採用ET。市場資料可能有所延遲。
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
日內區間
目前US$8.93
52週區間
目前US$8.93
盤中時間採用ET。市場資料可能有所延遲。
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
日內區間
目前US$8.93
52週區間
目前US$8.93
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 200萬 USD | — | — |
| 毛利 | — | — | 200萬 USD | — | — |
| 研究與開發 | 3905.4萬 USD | 3844.4萬 USD | 1977.7萬 USD | 2491.9萬 USD | 1934萬 USD |
| 銷售、一般及管理費用 | 1783.5萬 USD | 1601萬 USD | 1296.3萬 USD | 613.6萬 USD | 437.9萬 USD |
| 營業費用 | 5688.9萬 USD | 5445.4萬 USD | 3274萬 USD | 3105.5萬 USD | 2371.9萬 USD |
| 利息收入 | 585.1萬 USD | 888.7萬 USD | 286萬 USD | 55.3萬 USD | 2.6萬 USD |
| 折舊和攤銷 | — | — | — | 13萬 USD | — |
| 營業利益 | −5688.9萬 USD | −5445.4萬 USD | −3074萬 USD | −3105.5萬 USD | −2371.9萬 USD |
| 淨利 | −5103.8萬 USD | −4556.7萬 USD | −2787.6萬 USD | −3049.9萬 USD | −2444.2萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1909.62萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1386.18萬0.02%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1142.04萬0.12%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF684.89萬0.01%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB396.93萬0.04%108.2億 USD0.44%US$206.49+3.00%
iShares Russell 2000 Growth ETFIWO371.47萬0.03%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO346.32萬0.02%180億 USD0.06%US$112.66+0.50%
Dimensional - US Small Cap ETFDFAS236.98萬0.01%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
